Skip to main content

Table 1 Characteristics of included studies

From: Effect of vitamin D supplementation on cardiac-metabolic risk factors in elderly: a systematic review and meta-analysis of clinical trials

Author, year

Country

Study population

Study design

Sex

Sample size

Dose of

Vitamin D

(IU)

Mean age (SD)

Intervention duration

Baseline Vitamin D Level (nmol/L)

Mean (SD)

outcomes

Witham 2010

UK

DM

RCT

M/F

I1: 19

I2: 20

P: 22

Two single doses

I1: 100,000 IU

I2: 200,000 IU

I1:65.3 (11.1)

I2:63.3 (9.6)

P: 66.7 ( 9.7)

–

I1:48 (21)

I2:41(14)

P: 45 ( 17)

HOMA-IR

HbA1c

TC

Naharci 2012

Turkey

IFG

Non-RCT

M/F

I: 28

P: 23

Deficient:

300,000 IU/week

Insufficient:

880 IU/day

Normal:

400 IU/day

I: 75.1 (7.3)

P: 76.1( 5.4)

5 months

I: 47.5 (24.2)

P: 55.8 (37.4)

FBS

HOMA-IR

Insulin

TC, TG, LDL, HDL

LDL/HDL ratio

BMI

Witham 2012

UK

Patient with a history of stroke

RCT

M/F

I: 30

P: 28

A single dose 100,000 IU

I: 66.2 (13)

P: 67.7 ( 6.9)

-

I: 38.7 (17.6)

P: 38.7 (17.8)

TC

Wood 2012

UK

Postmenopausal women

RCT

F

I1:102

I2:101

P: 102

I1: 400 IU/day

I2: 1000 IU/day

I1: 63.5(1.9)

I2: 64.1 (2.3)

P: 63.9 (2.3)

12 months

I1:32.7(12.9)

I2:32.4(13.8)

P: 36.1 (17.1)

FBS

HOMA-IR

Insulin

TC, TG, LDL, HDL

Kim 2014

Korea

DM

RCT

M/F

I: 11

P: 13

1200 IU /day

I: 73.2 (2.0)

P: 70 (1.3)

12 weeks

I: 26.1(4.4)

P: 29.1 (6.9)

FBS

HOMA-IR

Insulin

TC, TG, LDL, HDL

BMI

El-Hajj Fuleihan 2017

Qatar

Overweight

RCT

M/F

High dose(I):

110

Low dose(P):

112

High dose(I):

3750 IU/day

Low dose(P):

600 IU/day

T: 71 (4)

12 months

I: 52.1(17.4)

P: 49.9(20.4)

FBS

HOMA-IR

HbA1c, Insulin

TC, TG, LDL, HDL

Walter Verrusio, 2017

Italy

Healthy

Before and After

M/F

200

4000 IU/day

T: 65.9 (9.8)

6 months

–

–

Prusik 2018

Poland

Healthy

RCT

M/F

I: 48

P: 31

4000 IU/day

T: 68.4 ( 5.0)

12 weeks

I: 45.1(22.7)

P: 60.4(30.2)

TC, TG, LDL, HDL

LDL/HDL ratio

BMI

El Hajj 2019

Lebanon

Healthy

RCT

M/F

I: 60

P: 55

10,000 IU/week

I: 73.05 (1.95)

P:73.56 (2.14)

6 months

I: 25.2 (6.9)

P:26.2 (2.14)

BMI

WC

Wenclewska 2019

Poland

Healthy & DM

RCT

M/F

I: 48

P: 44

2000 IU / day

I: 63.43(1.5)

P: 69.78 (2.1)

3 months

I: 18.2 (3.2)

P:18.0(2.1)

FBS

HOMA-IR

HbA1c

TC, TG, LDL, HDL

LDL/HDL ratio

BMI

Hoseini 2020

Iran

NAFLD

RCT

M/F

I: 10

P: 10

50,000 IU/week

I: 61.3 (1.4)

P: 62 (1.8)

8 weeks

I: 22.9 (4.3)

P: 24.0 (4.3)

FBS

HOMA-IR

Insulin

TC, TG, LDL, HDL

El Hajj 2020

Lebanon

DM

RCT

M/F

I: 45

P: 43

30,000 IU/week

I: 66.9 (4.1)

P: 65.7 (4.5)

6 months

I:14.8 (4.5)

P:15.0 (4.2)

FBS

HOMA-IR

HbA1c

TC, TG, LDL, HDL

BMI, WC

  1. RCT Randomized controlled trial, I Intervention, P Placebo, SD standard deviation, M male, F female, DM Diabetes mellitus, IFG Impaired fasting glucose, NAFLD Non- alcoholic fatty liver disease, IU International unit, HOMA-IR Homeostatic Model Assessment of Insulin Resistance, HbA1c Hemoglobin A1c, FBS Fasting blood sugar, TC Total cholesterol, TG Triglyceride, HDL high-density lipoprotein, LDL low-density lipoprotein, BMI Body mass index, WC Waist circumference
Back to article page

Diabetology & Metabolic Syndrome

ISSN: 1758-5996

Contact us